Atrys Health Increases Sales Fivefold in the First Half of 2021

Atrys Health’s sales soar in the first half of the year. The Spanish company, which specializes in telemedicine and radiotherapy, has released this Thursday a preview of the results for the first six months of 2021 in a report sent to BME Growth, in which it specifies that it closed the half-year with a turnover of $48.6 million (€41.7 million), compared to $9.7 million (€8.3 million) in the same period of 2020, which means a fivefold increase in its revenues.

The company also achieved a gross operating profit (EBITDA) of $8.7 million (€7.5 million) in the first six months of 2021, compared to the $1.6 million (€1.4 million) achieved in the first six months of fiscal 2020.

Atrys Health closes the first half of 2021 with EBITDA exceeding seven million euros

Atrys Health presents its financial results for the first six months of 2021 while announcing that it has reached an important collaboration agreement with the Champalimaud Foundation, one of the most internationally recognized institutions in the prevention, diagnosis, and treatment of cancer, for the joint performance of advanced diagnostic and therapeutic procedures using non-invasive approaches.

Located in Lisbon and a pioneer in the development of advanced biomedical research programs and high-precision radiation treatment techniques with an emphasis on radiotherapy with extreme fractionation, the Champalimaud Foundation combines clinical care with a research agenda, activities that it carries out at the Champalimaud Center.

Under this alliance, based on their shared commitment to advanced radiotherapy, non-invasive therapeutic procedures, and research, Atrys Health and Champalimaud will initiate the implementation of joint protocols and methodologies of excellence under the scientific direction of Carlo Greco, director of radiotherapy research at the Champalimaud Foundation.

The company has more than 2,500 professionals and is present in Spain, Portugal, Switzerland, and Latin America

Atrys Health has a team of more than 2,500 professionals and is present in Spain, Portugal, Switzerland, and Latin America. The company structures its prevention and precision activity around five business units: telemedicine, oncology, pathology, prevention, and big data. Through these, it carries out conventional and advanced radiotherapy treatments, performs diagnostic tests in its own network of laboratories, analyzes radiology, cardiology, ophthalmology, and dermatology tests telematically, and provides smart and big data and data management services to the healthcare sector.

In Portugal, Atrys Health has a hospital with high added value and comprehensive treatment of oncological diseases in Santa Maria da Feira, a genetic diagnosis laboratory specializing in predictive and preventive medicine in Porto, two nuclear medicine centers in Braga and Porto, a radiology center in Porto and now two radiotherapy centers, one in Évora and the other in Lisbon.

__

(Featured image by Ted Eytan CC BY-SA 2.0 via Flickr)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.